Silco Pharmaceuticals Limited

SILCOPHL

BD0495SILCO6

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
18.9 ^BDT	-1.56%		-1.56%	-19.23%

05-01	Silco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
02-07	Silco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Silco Pharmaceuticals Limited Recommends Dividend for the Year Ended June 30, 2019

October 27, 2019 at 11:04 am

The Board of Directors of Silco Pharmaceuticals Limited has recommended 2% cash and 10% stock dividend for the year ended on June 30, 2019.

Latest news about Silco Pharmaceuticals Limited

Silco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	04-30	CI
Silco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-06	CI
Silco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	11-29	CI
Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023	11-27	CI
Silco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022	23-01-10	CI
Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022	22-11-06	CI
37,316,700 Ordinary Shares of Silco Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 11-FEB-2022.	22-02-10	CI
Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2021	21-11-24	CI
Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2020	20-11-02	CI
Silco Pharmaceuticals Limited Reports Earnings Results for the Year Ended on June 30, 2020	20-11-02	CI
Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil Ltd	20-08-22	CI
27,053,300 Ordinary Shares of Silco Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 11-FEB-2020.	20-02-10	CI
Silco Pharmaceuticals Limited Recommends Dividend for the Year Ended June 30, 2019	19-10-27	CI
Silco Pharmaceuticals Limited Announces Earnings Results for the Third Quarter and Nine Months Ended Period Ended on 31 March 2019	19-06-12	CI
Silco Pharmaceuticals Limited has completed an IPO in the amount of BDT 300 million.	19-04-10	CI
Silco Pharmaceuticals Limited has filed an IPO in the amount of BDT 300 million.	18-08-19	CI

Chart Silco Pharmaceuticals Limited

Duration

Period

More charts

Silco Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in manufacturing and marketing of pharmaceuticals finished products in the categories of antibiotics, analgesics, anti-diabetics, narcotics, antipyratics, anti-inflammatory drugs, antiulcerants and multi medicines. The Company manufactures products in various dosage forms including tablet, capsule, liquid syrup, dry syrup, pellet, powder, and powder suspension. Its products include SEOFOL-PLUS, KTM-10, SILFENAC, Silcal-D, NAXSIL 500, MQ-4 Tablet, Sitova, ALOPIN-5, LOSART-P, AZOSIL, and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SILCO PHARMACEUTICALS LIMITED	-19.23%	16.7M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	347B
MERCK & CO., INC.	+15.66%	319B
ABBVIE INC.	+0.24%	274B
ASTRAZENECA PLC	+13.13%	238B
NOVARTIS AG	+7.01%	204B
ROCHE HOLDING AG	-6.50%	203B
AMGEN INC.	+4.23%	161B
PFIZER, INC.	-1.70%	160B